CLINICAL TRIALS

Liver / Hepatocellular Carcinoma Clinical Trials in Minnesota

10+ recruiting Liver / Hepatocellular Carcinoma trials in Minnesota, simplified into plain English.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

NOT YET RECRUITINGPhase 1

Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications

The purpose of this study is to assess the safety of autologous Adipose-Derived Mesenchymal Stem Cell for use in End-Stage Liver Disease patients undergoing the creation of a duct-to-duct anastomosis during Living Donor

NCT06649864 · Rochester
RECRUITINGPhase 1

A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer

This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy wi

NCT06005740 · Rochester
RECRUITINGPhase 2

Integrated Therapies for Alcohol Use in Alcohol-associated Liver Disease (ITAALD) Trial

This is a multicenter, randomized, double-blinded, placebo-controlled trial focused on the treatment of severe alcohol-associated hepatitis (sAH) and alcohol use disorder (AUD). The primary purpose of the study is to de

NCT07060638 · Rochester
RECRUITINGPhase 2

A Study of NST-6179 in Subjects With Intestinal Failure-Associated Liver Disease (IFALD).

This is a phase 2a, multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of NST-6179 in subjects with intestinal failure-a

NCT05919680 · Rochester
ACTIVE NOT RECRUITINGPhase 2

Role of Lisinopril in Preventing the Progression of Non-Alcoholic Fatty Liver Disease, RELIEF-NAFLD Study

This phase II trial investigates how well lisinopril may work in preventing the progression of non-alcoholic fatty liver disease (NAFLD). NAFLD is a condition where there is an accumulation of fatty cells in the liver. N

NCT04550481 · Rochester
ACTIVE NOT RECRUITING

HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B

This is an ancillary to the NIDDK-sponsored Hepatitis B Research Network (HBRN) Study Cohort Study NCT01263587. This study will examine the balance between immune regulatory and effector responses in hepatitis B-infected

NCT01298037 · Plymouth
RECRUITING

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

To acquire blood samples from subjects for various purposes, including: i) determining the sensitivity and specificity of select DNA methylation markers for the detection of various types of cancer, ii) identifying benig

NCT05181826 · Coon Rapids
ACTIVE NOT RECRUITINGPhase 3

A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )

This Phase 3 study is conducted to evaluate lanifibranor in adults with NASH and liver fibrosis histological stage F2 or F3

NCT04849728 · Minneapolis
RECRUITING

US National OCS Liver Perfusion (OLP) Registry

This Registry is a sponsor-initiated, multi-center, observational, post-approval registry with an independent academic oversight. TransMedics has contracted with United Network for Organ Sharing (UNOS) the Federal manag

NCT05940857 · Rochester
RECRUITINGPhase 1

Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.

The purpose of this study is to learn about the effects of study medicine (PF-08634404) when given alone or with another antibody (ipilimumab) for the treatment of a type of liver cancer called hepatocellular carcinoma (

NCT07227012 · Coon Rapids

RECOMMENDED RESOURCES FOR LIVER / HEPATOCELLULAR CARCINOMA

🛡️

GoHealth

Medicare Specialist

Compare Medicare Advantage and Supplement plans with a licensed advisor. Many patients with chronic conditions qualify for $0-premium plans with extra benefits.

Check Your Coverage →
💼

eHealth Insurance

Licensed Agents

Shop ACA health plans from top insurers. Licensed agents help you find coverage that works with clinical trial participation — at no cost to you.

Compare Plans Free →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Liver / Hepatocellular Carcinoma clinical trials in Minnesota?

Yes. Clinicals AI lists 10+ recruiting Liver / Hepatocellular Carcinoma trials in Minnesota sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Liver / Hepatocellular Carcinoma trial in Minnesota?

Eligibility varies by study. Most trials require a confirmed Liver / Hepatocellular Carcinoma diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Liver / Hepatocellular Carcinoma clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.